Developer docs
API playgroundTry for free, no card

Search company profiles

Breakout Ventures

Full company profile

uuid00006ur

Namestring
Breakout Ventures
Legal namestring
Breakout Management LLC
Websiteurl
breakout.vc
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Breakout Ventures is a San Francisco-based early-stage venture capital firm founded in 2016 by Lindy Fishburne and Julia Moore to back science-driven founders commercializing breakthroughs at the intersection of artificial intelligence and laboratory science — spanning biotech, tech-bio, chemistry, materials, neurotechnology, and hard tech. The firm operates through Breakout Management LLC, a Delaware-registered entity, and has built a portfolio of approximately 28 active and exited companies including Cytovale (FDA-cleared AI sepsis diagnostic), Surf Bio (acquired by Halozyme for up to $400M), Cortexyme (IPO 2019, now Quince Therapeutics), Twelve, ZymoChem, Noetik, and Modern Meadow.

The firm's core product is its third venture fund — Fund III, closed at $114 million in March 2026 — which deploys seed capital of $500,000 to $5,000,000 per company into at least 20 startups. Breakout's investment process relies on a PhD-trained partner bench (Dana Watt, Nima Ronaghi, Susanna Harris) supplemented by five venture partners and a fractional CFO and counsel, providing technical diligence and syndicate-stacking network access to portfolio companies. Complementary products include the Breakout Job Board / Talent Network (jobs.breakout.vc, operated via Getro) aggregating open roles across 26+ portfolio companies, and an LP investor portal (FundPanel.io and ShareFile).

Breakout generates revenue through standard venture fund economics: management fees on assets under management across Funds I, II and III, plus carried interest (typically 20%) on successful exits. The firm's capital base includes returning US institutional LPs (Cortes Capital, S-Cubed Capital, The Kraft Group, Pinegrove Venture Partners, LH Capital affiliate) and new international LPs (JIMCO, Korea Omega Investment Corporation). Portfolio support, talent network infrastructure, and the firm's decade-long specialization in AI-driven science positioning constitute its primary differentiation against generalist seed investors.

Short descriptiontext

Breakout Ventures is a San Francisco-based early-stage venture capital firm founded in 2016 that backs science-driven founders building AI-enabled companies in biotech, chemistry, neurotechnology, and hard tech, deploying seed checks of $500K–$5M from its $114M Fund III.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital fund, seed-stage investing, deep tech startups, biotech venture capital, science-driven investing
Industry2 codes
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code1 code
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Fund Management & Carried Interest
TypeManaged Services
Description

Breakout Ventures earns revenue as a venture capital firm managing multiple funds (Fund I, Fund II, Fund III). Revenue is generated via management fees on assets under management and carried interest (typically 20%) on successful exits. Notable Fund II exit: Surf Bio acquired by Halozyme Therapeutics for up to $400M (returning ~half of Fund II to LPs). Other Fund I exit: Cytovale developed FDA-cleared AI sepsis diagnostic. Fund III ($114M) actively deploying seed investments.

breakout.vc
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Breakout Ventures is a San Francisco-based venture capital firm that raises pooled funds from institutional limited partners and invests the capital as seed-stage checks ($500,000 to $5,000,000) into science-driven startups operating at the intersection of AI/computation and laboratory research — spanning biotech, tech-bio, deep tech, chem tech, hard tech, neurotechnology, sustainable fuels, diagnostics, and bio-based materials. The firm also operates the Breakout Job Board/Talent Network and an LP Investor Portal as portfolio-support services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Surf Bio acquired by Halozyme Therapeutics for $300M upfront + $100M in milestone payments (up to $400M total), returning approximately half of Fund II to LPs.
+3 more records
Product overview1 text field

Breakout Ventures is a San Francisco-based venture capital firm (founded 2016) whose product offering centers on its third venture fund, Breakout Ventures Fund III ($114M, closed March 2026), a single pooled investment vehicle targeting early-stage startups at the intersection of science, technology, and AI (biology, chemistry, AI diagnostics, sustainable fuels, neural interfaces, deep tech). Complementing the fund, Breakout operates the Breakout Ventures Talent Network / Job Board, a recruitment platform (jobs.breakout.vc, powered by Getro Inc.) that aggregates open roles across portfolio companies such as Parallel Bio, Zymochem, Twelve, Cytovale, Checkerspot, Transfyr, NOETIK, Constellation Systems, EnPlusOne Biosciences, Passkey, and Vitra Labs. A separate Investor Portal (FundPanel.io and ShareFile) serves limited partners. Together, Fund III is the core capital-allocation product, the Talent Network is an operational/portfolio-support service, and the Investor Portal provides LP-facing fund administration and document access.

Product and service3 records
1Breakout Ventures Fund III
CategoryVenture capital fund (core product)
Description

A $114 million venture capital fund (closed March 2026) that deploys seed-stage capital ($500,000–$5,000,000 per company) into early-stage, science-driven startups operating at the intersection of science, technology, and AI, with emphasis on biology, chemistry, AI diagnostics, sustainable fuels, neural interfaces, deep tech, and reshoring critical materials. Available to institutional limited partners.

2Breakout Ventures Talent Network / Job Board
CategoryPortfolio-support recruitment platform (service)
Description

An online recruitment platform (jobs.breakout.vc, powered by Getro Inc.) that aggregates open roles across Breakout's portfolio companies (e.g., Parallel Bio, ZymoChem, Twelve, Cytovale, Checkerspot, NOETIK, Constellation Systems, EnPlusOne Biosciences, Passkey, Vitra Labs) and includes job alerts, talent-network registration, and direct application submission for job-seekers.

3Breakout Ventures Investor Portal
CategoryLP-facing fund administration portal (service)
Description

Limited-partner investor login and document access (powered by FundPanel.io and ShareFile) provided to Fund III investors and related stakeholders for fund administration and reporting.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Acquiror of Breakout Ventures' portfolio company Surf Bio for up to $400M ($300M upfront + $100M milestones). The exit returned approximately half of Fund II to Breakout's limited partners and validated Breakout's thesis on stabilizing biologics to address drug delivery challenges.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Source of a stealth-mode portfolio company spinout (small-molecule discoveries) in which Breakout Ventures led the seed investment as one of the initial Fund III deployments.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Lux Capital is a New York-based early-stage VC investing at the intersection of science, technology, and frontier tech — including AI-bio, deep tech, and hard tech. Most direct peer to Breakout's AI × science thesis at the seed stage.

TypeDirect peer
Description

DCVC (Data Collective) is a San Francisco-based early-stage VC focused on deep tech at the intersection of computation and the physical and life sciences — including AI-bio, computational biology, and materials. Direct peer to Breakout's AI × science seed strategy.

TypeDirect peer
Description

ARCH Venture Partners is one of the longest-tenured science-driven VCs, backing early-stage companies in biotech, advanced materials, energy, and AI-enabled science. Direct peer for frontier-science seed investing with a comparable thesis on science × technology.

TypeDirect peer
Description

Atlas Venture is a Boston-based early-stage VC focused exclusively on building biotech startups, with deep domain expertise in drug discovery and platform technologies. Direct peer to Breakout's biotech seed strategy and one of the most established science-focused seed funds.

TypeDirect peer
Description

Section 32 is a San Diego-based early-stage VC founded by Bill Maris (founder of Google Ventures) investing at the frontier of science and technology, including biotech, AI, and hard tech. Direct peer for early-stage science-driven thesis investing.

TypeDirect peer
Description

Foresite Capital is a San Francisco-based healthcare and science-driven VC investing across biotech, genomics, and AI-enabled drug discovery at early stages. Direct peer with overlapping portfolio themes including AI-bio and frontier science.

TypeBroad incumbent
Description

Khosla Ventures is a much larger Menlo Park-based VC with a portfolio spanning AI, biotech, deep tech, and frontier science. A broad incumbent in the same space with substantially more capital and brand recognition, competing for science-driven seed deals.

TypeBroad incumbent
Description

Andreessen Horowitz's Bio Fund invests at the intersection of biology and technology, including AI-bio and computational drug discovery. A broad incumbent with a much larger fund size and broader portfolio competing in the same AI-bio seed space as Breakout.

TypeDirect peer
Description

SOSV is a multi-stage VC running accelerator programs (including HAX for hardware, IndieBio for biology, and others) focused on deep tech and biotech at the earliest stages. Direct peer for seed-stage science-driven investing with global reach.

TypeEmerging player
Description

Petri is an early-stage VC specifically focused on programmable biology and AI-bio at the seed stage. Emerging player with a closely overlapping thesis on AI × biology investment, although with a narrower programmatic focus than Breakout's broader deep-tech remit.

Market position
Strengths2 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment50 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Breakout Ventures

Venture Capitalbreakout.vc

Breakout Ventures is a San Francisco-based early-stage venture capital firm founded in 2016 that backs science-driven founders building AI-enabled companies in biotech, chemistry, neurotechnology, and hard tech, deploying seed checks of $500K–$5M from its $114M Fund III.

What Breakout Ventures does

Breakout Ventures is a San Francisco-based early-stage venture capital firm founded in 2016 by Lindy Fishburne and Julia Moore to back science-driven founders commercializing breakthroughs at the intersection of artificial intelligence and laboratory science — spanning biotech, tech-bio, chemistry, materials, neurotechnology, and hard tech. The firm operates through Breakout Management LLC, a Delaware-registered entity, and has built a portfolio of approximately 28 active and exited companies including Cytovale (FDA-cleared AI sepsis diagnostic), Surf Bio (acquired by Halozyme for up to $400M), Cortexyme (IPO 2019, now Quince Therapeutics), Twelve, ZymoChem, Noetik, and Modern Meadow.

The firm's core product is its third venture fund — Fund III, closed at $114 million in March 2026 — which deploys seed capital of $500,000 to $5,000,000 per company into at least 20 startups. Breakout's investment process relies on a PhD-trained partner bench (Dana Watt, Nima Ronaghi, Susanna Harris) supplemented by five venture partners and a fractional CFO and counsel, providing technical diligence and syndicate-stacking network access to portfolio companies. Complementary products include the Breakout Job Board / Talent Network (jobs.breakout.vc, operated via Getro) aggregating open roles across 26+ portfolio companies, and an LP investor portal (FundPanel.io and ShareFile).

Breakout generates revenue through standard venture fund economics: management fees on assets under management across Funds I, II and III, plus carried interest (typically 20%) on successful exits. The firm's capital base includes returning US institutional LPs (Cortes Capital, S-Cubed Capital, The Kraft Group, Pinegrove Venture Partners, LH Capital affiliate) and new international LPs (JIMCO, Korea Omega Investment Corporation). Portfolio support, talent network infrastructure, and the firm's decade-long specialization in AI-driven science positioning constitute its primary differentiation against generalist seed investors.

Breakout Ventures firmographics

Firmographics
Name
Breakout Ventures
Legal name
Breakout Management LLC
Website
https://breakout.vc
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Breakout Ventures is a San Francisco-based early-stage venture capital firm founded in 2016 that backs science-driven founders building AI-enabled companies in biotech, chemistry, neurotechnology, and hard tech, deploying seed checks of $500K–$5M from its $114M Fund III.
Ownership category
akta.pro rank

Breakout Ventures industry classification

Industry
Product category
Venture Capital
NAICS
Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Venture capital fund
  • Seed-stage investing
  • Deep tech startups
  • Biotech venture capital
  • Science-driven investing

Where Breakout Ventures is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Breakout Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Venture Fund Management & Carried Interest: Breakout Ventures earns revenue as a venture capital firm managing multiple funds (Fund I, Fund II, Fund III). Revenue is generated via management fees on assets under management and carried interest (typically 20%) on successful exits. Notable Fund II exit: Surf Bio acquired by Halozyme Therapeutics for up to $400M (returning ~half of Fund II to LPs). Other Fund I exit: Cytovale developed FDA-cleared AI sepsis diagnostic. Fund III ($114M) actively deploying seed investments.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Breakout Ventures product offering

Product offering

Core offering

Breakout Ventures is a San Francisco-based venture capital firm that raises pooled funds from institutional limited partners and invests the capital as seed-stage checks ($500,000 to $5,000,000) into science-driven startups operating at the intersection of AI/computation and laboratory research — spanning biotech, tech-bio, deep tech, chem tech, hard tech, neurotechnology, sustainable fuels, diagnostics, and bio-based materials. The firm also operates the Breakout Job Board/Talent Network and an LP Investor Portal as portfolio-support services.

Product overview

Breakout Ventures is a San Francisco-based venture capital firm (founded 2016) whose product offering centers on its third venture fund, Breakout Ventures Fund III ($114M, closed March 2026), a single pooled investment vehicle targeting early-stage startups at the intersection of science, technology, and AI (biology, chemistry, AI diagnostics, sustainable fuels, neural interfaces, deep tech). Complementing the fund, Breakout operates the Breakout Ventures Talent Network / Job Board, a recruitment platform (jobs.breakout.vc, powered by Getro Inc.) that aggregates open roles across portfolio companies such as Parallel Bio, Zymochem, Twelve, Cytovale, Checkerspot, Transfyr, NOETIK, Constellation Systems, EnPlusOne Biosciences, Passkey, and Vitra Labs. A separate Investor Portal (FundPanel.io and ShareFile) serves limited partners. Together, Fund III is the core capital-allocation product, the Talent Network is an operational/portfolio-support service, and the Investor Portal provides LP-facing fund administration and document access.

Differentiator

Problem solved

Functional benefit

Products and services

  • Breakout Ventures Fund III A $114 million venture capital fund (closed March 2026) that deploys seed-stage capital ($500,000–$5,000,000 per company) into early-stage, science-driven startups operating at the intersection of science, technology, and AI, with emphasis on biology, chemistry, AI diagnostics, sustainable fuels, neural interfaces, deep tech, and reshoring critical materials. Available to institutional limited partners.
  • Breakout Ventures Talent Network / Job Board An online recruitment platform (jobs.breakout.vc, powered by Getro Inc.) that aggregates open roles across Breakout's portfolio companies (e.g., Parallel Bio, ZymoChem, Twelve, Cytovale, Checkerspot, NOETIK, Constellation Systems, EnPlusOne Biosciences, Passkey, Vitra Labs) and includes job alerts, talent-network registration, and direct application submission for job-seekers.
  • Breakout Ventures Investor Portal Limited-partner investor login and document access (powered by FundPanel.io and ShareFile) provided to Fund III investors and related stakeholders for fund administration and reporting.

Quantifiable outcome

  • Surf Bio acquired by Halozyme Therapeutics for $300M upfront + $100M in milestone payments (up to $400M total), returning approximately half of Fund II to LPs.
  • +3 more outcomes

Companies that use Breakout Ventures

Customer profile

Segments3 records

Ideal customer profiles2 records

Breakout Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

Feature3 records

Breakout Ventures partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and minor.

  • Halozyme TherapeuticsflagshipStrategic or Co-development PartnerAcquiror of Breakout Ventures' portfolio company Surf Bio for up to $400M ($300M upfront + $100M milestones). The exit returned approximately half of Fund II to Breakout's limited partners and validated Breakout's thesis on stabilizing biologics to address drug delivery challenges.
  • University of ChicagominorStrategic or Co-development PartnerSource of a stealth-mode portfolio company spinout (small-molecule discoveries) in which Breakout Ventures led the seed investment as one of the initial Fund III deployments.

Scale indicators6 records

Recent moves5 records

Expansion highlights6 records

Breakout Ventures competitors and assessment

Company assessment

Direct peers

  • Lux Capital: Lux Capital is a New York-based early-stage VC investing at the intersection of science, technology, and frontier tech — including AI-bio, deep tech, and hard tech. Most direct peer to Breakout's AI × science thesis at the seed stage.
  • DCVC: DCVC (Data Collective) is a San Francisco-based early-stage VC focused on deep tech at the intersection of computation and the physical and life sciences — including AI-bio, computational biology, and materials. Direct peer to Breakout's AI × science seed strategy.
  • ARCH Venture Partners: ARCH Venture Partners is one of the longest-tenured science-driven VCs, backing early-stage companies in biotech, advanced materials, energy, and AI-enabled science. Direct peer for frontier-science seed investing with a comparable thesis on science × technology.
  • Atlas Venture: Atlas Venture is a Boston-based early-stage VC focused exclusively on building biotech startups, with deep domain expertise in drug discovery and platform technologies. Direct peer to Breakout's biotech seed strategy and one of the most established science-focused seed funds.
  • Section 32: Section 32 is a San Diego-based early-stage VC founded by Bill Maris (founder of Google Ventures) investing at the frontier of science and technology, including biotech, AI, and hard tech. Direct peer for early-stage science-driven thesis investing.
  • Foresite Capital: Foresite Capital is a San Francisco-based healthcare and science-driven VC investing across biotech, genomics, and AI-enabled drug discovery at early stages. Direct peer with overlapping portfolio themes including AI-bio and frontier science.
  • SOSV: SOSV is a multi-stage VC running accelerator programs (including HAX for hardware, IndieBio for biology, and others) focused on deep tech and biotech at the earliest stages. Direct peer for seed-stage science-driven investing with global reach.

Broad incumbents

  • Khosla Ventures: Khosla Ventures is a much larger Menlo Park-based VC with a portfolio spanning AI, biotech, deep tech, and frontier science. A broad incumbent in the same space with substantially more capital and brand recognition, competing for science-driven seed deals.
  • Andreessen Horowitz (a16z) Bio Fund: Andreessen Horowitz's Bio Fund invests at the intersection of biology and technology, including AI-bio and computational drug discovery. A broad incumbent with a much larger fund size and broader portfolio competing in the same AI-bio seed space as Breakout.

Emerging players

  • Petri.bio / Petri Bio (formerly Petri): Petri is an early-stage VC specifically focused on programmable biology and AI-bio at the seed stage. Emerging player with a closely overlapping thesis on AI × biology investment, although with a narrower programmatic focus than Breakout's broader deep-tech remit.

Market position

Strengths2 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Breakout Ventures social profiles

Digital presence

Breakout Ventures compliance and trust

Trust signal

Compliance4 records

Breakout Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Breakout Ventures leadership team

Management profile

Number of profiles

Profiles13 records

Breakout Ventures funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Breakout Ventures M&A and investment

M&A and investment

M&A

Investments50 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Breakout Ventures

What does Breakout Ventures do?

Breakout Ventures is a San Francisco-based venture capital firm that raises pooled funds from institutional limited partners and invests the capital as seed-stage checks ($500,000 to $5,000,000) into science-driven startups operating at the intersection of AI/computation and laboratory research — spanning biotech, tech-bio, deep tech, chem tech, hard tech, neurotechnology, sustainable fuels, diagnostics, and bio-based materials. The firm also operates the Breakout Job Board/Talent Network and an LP Investor Portal as portfolio-support services.

Is Breakout Ventures a public or private company?

Breakout Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Breakout Ventures founded?

Breakout Ventures was founded in 2016. It employs 11 to 50 people.

Where is Breakout Ventures based?

Breakout Ventures is headquartered in San Francisco, United States, in the North America region.

How does Breakout Ventures make money?

One revenue line is on record: venture Fund Management & Carried Interest.

Who are Breakout Ventures's main competitors?

Direct peers on record are Lux Capital, DCVC, ARCH Venture Partners, Atlas Venture, Section 32, Foresite Capital and SOSV. Broad incumbents are Khosla Ventures and Andreessen Horowitz (a16z) Bio Fund. Petri.bio / Petri Bio (formerly Petri) is listed as an emerging player.

Does Breakout Ventures have an API?

No public API is recorded for Breakout Ventures.

What industry is Breakout Ventures in?

Breakout Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Venture Capital Access OnlineTransfyr Launches Physical AI Platform for Science with $25M Seed FundingTransfyr, a physical AI platform for science, launched with $25 million in seed funding led by General Catalyst. The company aims to capture hands-on bench science into machine-readable data to improve reproducibility and automation. It is hiring engineers and AI researchers in Cambridge, MA.BloombergWatch AI Frenzy Splits VC Into Winners and Have-Nots - BloombergVenture capital firms are experiencing a divergence in performance due to the AI investment boom, with some firms securing significant returns while others lag behind. The article features insights from executives at Breakout Ventures, Salesforce Ventures, and Dell Technologies Capital regarding this market split.MedCity NewsWhat Health Tech Investors Love in Founders — and What They Can’t StandAt MedCity News' Bullseye event in Chicago, three healthcare investors from Town Hall Ventures, Breakout Ventures, and Mayo Clinic discussed founder qualities they value, emphasizing adaptability, willingness to pivot, and self-awareness over blind confidence. The panelists noted that in a sector where regulation and technology are evolving rapidly, founders who have previously failed or pivoted demonstrate more valuable adaptability. They also highlighted that successful founders must be able to attract top talent, even competing against major AI labs like OpenAI, which requires exceptional leadership qualities.Pulse 2.0AquaPoro Raises $5 Million To Generate Net New Water From AirAquaPoro Technologies announced it raised $5 million in seed financing led by Breakout Ventures, with participation from Cerberus Ventures, Humba Ventures, and One Small Planet, to advance its atmospheric water technology. The funding will accelerate manufacturing scale-up and support deployment of the company's first commercial pilot installations, including what the company calls the world's first continuous-flow atmospheric water harvesting system at UC Riverside. AquaPoro's ALMA technology extracts clean water from ambient air using a continuous-flow process designed to integrate into manufacturing facilities.FinancialContent Business PageAquaPoro Raises $5M to Advance Technology that Generates Net New Water from AirAquaPoro Technologies Inc., a deep tech startup developing atmospheric water generation systems, has closed a $5 million seed financing round led by Breakout Ventures with participation from Cerberus Ventures, Humba Ventures, and One Small Planet. The funding will accelerate manufacturing scale-up and the deployment of the company's first commercial pilot installations using its proprietary ALMA™ technology, which extracts clean water from ambient air at lower energy and cost than conventional systems. The company is set to break ground on the world's first continuous-flow atmospheric water harvesting system at UC Riverside in partnership with CE-CERT, with commercial interest already from a leading national beverage manufacturer and a multinational water treatment company.FinSMEsAquaPoro Raises $5M in Seed FundingAquaPoro Technologies, a San Diego-based startup, raised $5M in seed funding led by Breakout Ventures with participation from Cerberus, Humba, and One Small Planet. The company will use the funds to accelerate manufacturing scale-up and deploy its first commercial pilot installations. AquaPoro engineers atmospheric water systems that operate below conventional humidity thresholds.TrendHunter.comAI-Driven Science FundsBreakout Ventures closed its third venture fund, Fund III, at $114 million to invest in AI-powered science startups from pre-seed through Series A. The fund is led by founders Lindy Fishburne and Julia Moore and targets companies where computation and lab research converge, including drug discovery, diagnostics, neurotechnology, and bio-based materials. The closure signals growing investor conviction that AI-native approaches can compress discovery timelines and create scientific moats for scientist-founders building engineering-minded labs.Pulse 2.0Breakout Ventures: $114 Million Fund III Launched To Back Frontier Science StartupsBreakout Ventures announced the close of its $114 million Fund III, a venture capital vehicle focused on science-driven startups at the intersection of biology, chemistry, and artificial intelligence, with backing from both returning and new limited partners. The San Francisco-based firm highlighted strong prior fund performance, including portfolio company Surf Bio's acquisition by Halozyme for up to $400 million and a $50 million upfront partnership between Noetik and GSK for AI-driven cancer research. Breakout Ventures has already begun deploying Fund III capital with initial seed investments targeting companies leveraging AI to address complex scientific challenges.Phirda1.14 亿美元!Breakout 押注 AI 生物赛道Breakout Ventures announced a $114 million fund on March 10, targeting AI and biotech founder-led startups. The fund has already made seed investments, including in a University of Chicago spinoff. Breakout cites prior exits like Surf Bio and Noetik as backing.CXO DigitalpulseBreakout Ventures Raises $114M Fund to Back AI-Driven Science Startups VentureVenture capital firm Breakout Ventures has raised a $114 million Fund III to support early-stage startups combining artificial intelligence with scientific research in fields such as biology and chemistry. The firm plans to invest in at least 20 startups, with typical investment sizes ranging from $500,000 to $5 million each. The fundraising, completed over 18 months from institutional investors, reflects a growing venture capital trend of backing companies operating at the intersection of AI and deep science.